Marfan's syndrome future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
(Created page with "==Future Therapies and Investigations== There is no cure for Marfan syndrome, but life expectancy has increased significantly over the last few decades, and clinical trials ar...") |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Marfan's syndrome}} | |||
'''Editors-In-Chief:''' [[William James Gibson]], [[C. Michael Gibson, M.S., M.D.]] | |||
'''Associate Editor-In-Chief:''' {{CZ}} ; {{CA}} | |||
==Overview== | |||
==Future Therapies and Investigations== | ==Future Therapies and Investigations== | ||
There is no cure for Marfan syndrome, but life expectancy has increased significantly over the last few decades, and clinical trials are underway for a promising new treatment. | * Research in laboratory mice has suggested that the [[angiotensin II receptor antagonist]] [[losartan]], which appears to block TGF-beta activity, can slow or halt the formation of aortic aneurysms in Marfan syndrome.<ref name="scimag">{{Cite journal | last = Habashi | first = Jennifer P. | coauthors = Daniel P. Judge, Tammy M. Holm, Ronald D. Cohn, Bart L. Loeys, Timothy K. Cooper, Loretha Myers, Erin C. Klein, Guosheng Liu, Carla Calvi, Megan Podowski, Enid R. Neptune, Marc K. Halushka, Djahida Bedja, Kathleen Gabrielson, Daniel B. Rifkin, Luca Carta, Francesco Ramirez, David L. Huso, and Harry C. Dietz | date = April 7, 2006 | title = Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome | volume = 312 | issue = 5770 | pages = 117 - 121 | doi = 10.1126/science.1124287 | url = http://www.sciencemag.org/cgi/content/full/312/5770/117 | abstract = http://www.sciencemag.org/cgi/content/abstract/sci;312/5770/117 | news = http://www.news-medical.net/?id=17249}}</ref> A large [[clinical trial]] sponsored by the [[National Institutes of Health]] comparing the effects of losartan and [[atenolol]] on the aortas of Marfan patients is scheduled to begin in early 2007, coordinated by Johns Hopkins.<ref name="trial">{{Cite web|url=http://www.marfan.org/nmf/GetSubContentRequestHandler.do?sub_menu_item_content_id=147&menu_item_id=91|title=Atenolol vs. Losartan in Individuals with Marfan Syndrome Clinial Trial|publisher=National Marfan Foundation}}</ref> | ||
* There is no cure for Marfan syndrome, but life expectancy has increased significantly over the last few decades, and clinical trials are underway for a promising new treatment. The syndrome is treated by addressing each issue as it arises, and, in particular, considering prophylactic medication, even for young children, to slow progression of aortic dilation. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 15:39, 22 August 2012
|
Marfan's syndrome Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Marfan's syndrome future or investigational therapies On the Web | |
|
American Roentgen Ray Society Images of Marfan's syndrome future or investigational therapies | |
|
FDA on Marfan's syndrome future or investigational therapies | |
|
Marfan's syndrome future or investigational therapies in the news | |
|
Blogs on Marfan's syndrome future or investigational therapies | |
|
Risk calculators and risk factors for Marfan's syndrome future or investigational therapies | |
Editors-In-Chief: William James Gibson, C. Michael Gibson, M.S., M.D.
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [1] ; Assistant Editor-In-Chief: Cassandra Abueg, M.P.H. [2]
Overview
Future Therapies and Investigations
- Research in laboratory mice has suggested that the angiotensin II receptor antagonist losartan, which appears to block TGF-beta activity, can slow or halt the formation of aortic aneurysms in Marfan syndrome.[1] A large clinical trial sponsored by the National Institutes of Health comparing the effects of losartan and atenolol on the aortas of Marfan patients is scheduled to begin in early 2007, coordinated by Johns Hopkins.[2]
- There is no cure for Marfan syndrome, but life expectancy has increased significantly over the last few decades, and clinical trials are underway for a promising new treatment. The syndrome is treated by addressing each issue as it arises, and, in particular, considering prophylactic medication, even for young children, to slow progression of aortic dilation.
References
- ↑ Habashi, Jennifer P. (April 7, 2006). "Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome". 312 (5770): 117–121. doi:10.1126/science.1124287. Unknown parameter
|news=ignored (|newspaper=suggested) (help); Unknown parameter|abstract=ignored (help); Unknown parameter|coauthors=ignored (help) - ↑ "Atenolol vs. Losartan in Individuals with Marfan Syndrome Clinial Trial". National Marfan Foundation.